 4. The investigator will select the appropriate treatment arm for the patient with the following requirements: a Patients cannot have had prior progression or intolerance on the single agent chemotherapy and then enrolled on an arm with that same single agent chemotherapy plus nivolumab b The chemotherapy on the arm selected must be considered standard of care or its components listed in the NCCN guidelines for that cancer type. 